Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023

Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023

Abstract Seroprevalence studies on SARS-CoV-2 are essential for estimating actual prevalence rates of infection and vaccination in communities. This study evaluated infection rates based on total anti-nucleocapsid immunoglobulin (N) and/or infection history. We determined the seroprevalence of anti-...

Full description

Bibliographic Details
Main Authors: Jira Chansaenroj, Nungruthai Suntronwong, Sitthichai Kanokudom, Suvichada Assawakosri, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Lakana Wongsrisang, Thanunrat Thongmee, Ratchadawan Aeemjinda, Nongkanok Khanarat, Donchida Srimuan, Thaksaporn Thatsanathorn, Ritthideach Yorsaeng, Apirat Katanyutanon, Wichai Thanasopon, Wichan Bhunyakitikorn, Chaninan Sonthichai, Piyada Angsuwatcharakorn, Withak Withaksabut, Nasamon Wanlapakorn, Natthinee Sudhinaraset, Yong Poovorawan
Format: Article
Language:English
Published: Nature Portfolio 2023-09-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-42754-2

Internet

https://doi.org/10.1038/s41598-023-42754-2

Similar Items